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Abstract
A large number of studies have investigated gastrointestinal microbiota and
changes in the gastrointestinal community. However, a concern in these studies is
how best to assess changes in gastrointestinal community structure. This paper
presents two different human trials where the fecal terminal restriction fragment
length polymorphism data sets were analyzed to search for treatment effects.
Principle components analysis and cluster analysis based on grouped data are
compared with analysis of data by subject using distance coefficients. Comparison
with baseline within an individual before grouping by treatment provided a clearer
indication of treatment effects than did an evaluation of data grouped before
analysis. In addition, a large within-subject sample size and multiple baseline
samples are necessary to accurately analyze treatment effects.
Keywords
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Introduction
The gut is the largest mucosal surface in the body and the
microbial community present can have a large effect on
immune function. This community consists of a large
number of different species, which differ between the
mucosa and the feces (Zoetendal et al., 2002). However,
most human studies utilize fecal samples because of their
accessibility. The role the intestinal microbiota plays in the
protection against infection, especially by potentially patho
genic microorganisms, is well documented (Fuller, 1991).
Antibiotics are known to disrupt the normal intestinal
microbiota. They can cause disturbance in normal bowel
function, disruption of mucosal integrity, and symptoms
including diarrhea, bloating, flatulence, and intestinal pain.
Antibiotic therapy can also result in Clostridium difficile
colitis, which can cause severe symptoms (Bergogne-Bere
zin, 2000). Other treatments that affect the gastrointestinal
microbiota include the ingestion of probiotics and prebio
tics. Probiotics are defined as live microorganisms adminis
tered in adequate amounts to confer a beneficial health
effect on the host (FAO/WHO, 2001). Prebiotics are non-

digestible substances that when consumed provide a bene
ficial physiological effect on the host by selectively
stimulating the favorable growth or activity of a limited
number of indigenous bacteria (Gibson & Roberfroid,
1995). Probiotic treatment can facilitate gut normalization
after antibiotic treatment and probiotic bacteria can pro
duce a variety of health benefits including reduction in the
intensity and duration of diarrheal illness, improvement in
immune system function, alleviation of lactose intolerance,
and anticarcinogenic effects (Sanders, 1999; Gill & Guarner,
2004). Probiotics, primarily Lactobacillus and Bifidobacter
ium species, are found in many dairy foods and supple
ments. However, when fed to healthy subjects, probiotics
only modestly affect fecal microbiota and the strains used do
not tend to be permanent colonizers (Chen et al., 1999;
Tannock et al., 2000).
A large number of studies have been performed investi
gating fecal communities and changes in fecal communities.
However, it is difficult to assess changes in fecal community
structure. A number of different methods have been used:
standard plating on selective media (Sullivan et al., 2003;
Madden et al., 2005) and different rRNA gene-based

molecular methods including the use of group and species
speciﬁc primers or probes (Kok et al., 1996; Song et al., 2000;
Walter et al., 2001; Matsuki et al., 2002; Silvi et al., 2003),
denaturing gradient or temperature gradient gel electro
phoresis (DGGE or TGGE) analysis (Simpson et al., 2000;
Satokari et al., 2001; Heilig et al., 2002), cloning and
sequencing (Wilson & Blitchington, 1996; Leser et al.,
2002), and terminal restriction fragment length polymorph
ism (TRFLP) analysis (Kaplan et al., 2001; Sakata et al.,
2005; Jernberg et al., 2005). PCR methods are generally
thought to be superior to culture methods in that many fecal
species are not culturable using standard techniques. Clon
ing can provide very detailed phylogenetic information, but
is costly and labor intensive and is thus not realistic for
processing large numbers of samples. DGGE and TRFLP are
the best methods for rapid high throughput comparison of
bacterial communities. However, DGGE primarily provides
presence/absence information and is not easily digitized
(Forney et al., 2004). TRFLP data are good for characteriza
tion of bacterial communities because they can be used to
determine both species dominance and species richness
within samples and they are automatically digitized. Differ
ent phylotypes of bacteria present in each sample can also be
tentatively identiﬁed by comparison with a database (Kitts,
2001).
TRFLP data are generally analyzed using multivariate
statistical techniques such as canonical correspondence
analysis (Ayala-del-Rio et al., 2004), principle components
analysis (Clement et al., 1998; Kaplan & Kitts, 2004) or
cluster analysis (Urakawa et al., 2000; Hiraishi et al., 2000;
Kitts, 2001). Distance or similarity coefﬁcients are implicit
in all these methods for analysis of TRFLP data. Euclidean
distance is commonly used and is an implicit part of
principle components analysis, but is not appropriate for
data with a large number of zeros (Rees et al., 2004). Jaccard,
Dice, Sorensen’s and Simpson’s coefﬁcients are appropriate
for presence/absence analysis but ignore species abundance.
Bray–Curtis similarity is superior to other coefﬁcients for
analysis of TRFLP data because it can better handle the large
amounts of zeros present in TRFLP data and has high
statistical power and robustness with species abundance
data (Faith et al., 1991; Rees et al., 2004). Culture data can
also be treated as multivariate data and Euclidean distance is
then an appropriate coefﬁcient of similarity.
Any statistical analysis of fecal community structure
needs to take into account that human subjects tend to have
individually unique intestinal communities which may or
may not be stable over time (Zoetendal et al., 1998; Vaughan
et al., 2000; Vanhoutte et al., 2004). This makes analysis of
the data difﬁcult because, traditionally, data from multiple
subjects are analyzed as a group using either univariate
statistics with culture data or principle components analy
sis/cluster analysis with multivariate (i.e. TRFLP) data.

Grouping of fecal community data before analysis can result
in loss of statistical signiﬁcance or false negative results. The
approach outlined in this study involves the use of Bray–
Curtis similarity to measure an individual’s divergence from
baseline after treatment. This can overcome the problem of
subject-to-subject variability because subjects are analyzed
individually before treatment group differences are assessed.
This paper presents two different human trials where the
fecal TRFLP data sets were analyzed to search for treatment
effects. Analyses based on grouped data are compared with
individual data. Culture data from one of the studies were
also analyzed.

Methods
Probiotic--prebiotic study design
This randomized, double blind, placebo-controlled, parallel
group dietary study comprised two independent blocks of
32 healthy subjects each. The delivery device was 200 mL of
pasteurized whole yogurt, consumed twice daily, at least 8 h
apart. The probiotics consisted of Lactobacillus rhamnosus
strain 271 (Probi AB, Lund, Sweden), Lactobacillus acido
philus strain NCFM (Danisco, Madison, WI), Lactobacillus
paracasei ssp. paracasei strain DN114001 (Danone, Paris,
France), and Biﬁdobacterium sp. strain DN BIO 173010 (Le
Plessis, Robinson, France). The prebiotic was Frutaﬁts, a
type of inulin. All subjects were given control yogurt for the
ﬁrst 3 weeks, and were then randomly assigned to four
groups and allocated different experimental yogurts. Group
1 was fed a yogurt with added probiotic cultures [105–106
colony-forming units (CFU) of each culture per mL]. Group
2 was fed a yogurt with both added probiotic cultures
(105–106 CFU of each culture per mL) and the prebiotic
(5% weight in volume, w/v). Group 3 was fed a yogurt
supplemented with only the prebiotic (5% w/v). Group 4,
the control, was kept on the control yogurt with no additives
(all yogurt products were manufactured by Leatherhead
Food RA, Surrey, UK). At the end of week 9, all groups were
then given the control yogurt for a further 3 weeks. Fecal
samples were collected into sterile bags (weeks 3, 9, and 12)
and were immediately placed on ice and stored at �20 1C
until analysis. By the end of the study, 45 people had
complete sample sets from all three sampling times and
were used to assess the effects of probiotics and prebiotics on
fecal bacterial communities.

Probiotic--antibiotic study design
Healthy individuals were recruited who agreed to a 1-week
antibiotic treatment for study purposes only, receiving the
broad-spectrum (Gram-positive and Gram-negative) anti
biotic AugmentinTM (GlaxoSmithKline, Brentford, Lon
don), a mixture of amoxicillin and clavulanic acid, 875 mg

orally twice a day. This antibiotic was selected because of a
high rate of antibiotic-associated diarrhea. Patients were
then randomly assigned (1 : 1) to either the placebo or the
probiotic test product, which consisted of a capsule contain
ing a dried bacterial preparation of probiotic bacteria in the
genera Lactobacillus and Biﬁdobacterium. The following
strains and amounts were fed to individuals in the probiotic
group: Biﬁdobacterium biﬁdum Bb-02 (5 � 108), Biﬁdobac
terium lactis Bl-04 (5 � 109), B. lactis Bi-07 (5 � 109), Lacto
bacillus acidophilus NCFM (5 � 109), and Lactobacillus
paracasei Lpc-37 (5 � 109) (Danisco). The total dose of probiotic was 2 � 1010 bid (4 � 1010 daily). The other group
received a placebo consisting of the same ﬁller used in the
bacterial preparation, maltodextran, without the bacteria.
The study was conducted over 48 days. Three baseline (no
treatment) fecal samples were obtained on days 1, 7, and 14,
followed by the 7-day course of AugmentinTM. Fecal samples
were then collected on days 21, 25, 34, and 48. Probiotic
or placebo treatment began on day 14 and continued until
day 34.
Forty subjects were recruited with enrollment criteria
permitting only patients over 18 years old without signiﬁ
cant acute or chronic illnesses. Permitted medications
included those that were constant throughout the study if
they had no established or suspected impact on gut microbiota. Individuals were excluded if they were pregnant, were
breastfeeding, had a penicillin allergy, a history of gastro
intestinal illness or had been on any antibiotics in the
preceding 4 weeks. Fermented foods or any probiotic pre
parations were prohibited for 4 weeks before entry into the
study and throughout the duration of the study.
Fecal samples were obtained for TRF analysis by adding
approximately 1 g of feces to a 2 mL screw-cap tube and
freezing at �80 1C until shipment. For culture analyses, 5 g
of each fecal sample were placed into 16 mL Cary Blair
Transport Medium (Difco, Franklin Lakes, NJ) with indica
tor (Remel, Lenexa, KS) resulting in a 1 : 4.2 dilution factor.
The sample was then shaken/vortexed brieﬂy to disperse it
and frozen at �80 1C until shipment.

Bacterial culturing (probiotic--antibiotic study)
Frozen samples received from the clinical study were stored
at �80 1C until enumeration, and thawed at 37 1C immedi
ately prior to plating. Duplicate serial dilutions of the
samples were prepared (10�2–10�8) in sterile, prereduced
1% yeast extract. In accordance with Summanen et al.
(1993), liquid media were boiled for 5 min to drive off
dissolved oxygen and used within the same day. Yeast extract
diluent was autoclaved for 15 min at 121 1C and allowed to
cool prior to being placed in the anaerobic chamber and
dispensed into sterile tubes. All fecal samples were thawed,
diluted, and plated in an anaerobic chamber (Coy Labora

tory Products, Grass Lake, MI), maintained at 37 1C for 3–5
days in an atmosphere of 85% nitrogen, 10% hydrogen, and
5% carbon dioxide.
Dilutions were plated onto duplicate plates. Biﬁdobac
teria were enumerated using BIM-25 (Muñoa & Pares, 1988;
Lapierre et al., 1992; Rada et al., 1999), which is a reinforced
clostridial agar base containing polymixin B, tetrazolium
red, iodoacetate, kanamycin, and naladixic acid (SigmaAldrich, St Louis, MO). Lactobacilli were enumerated using
LBS Agar (Difco) plus 200 mL L�1 tomato juice from con
centrate (Campbell Soup, Camden, NJ) (Rogosa et al., 1951;
Sabine & Vaselekos, 1965). Organisms in the Bacteroides
fragilis group were enumerated with Bacteroides Bile Esculin
Agar (BBE; Difco). Clostridium species were enumerated
with Egg Yolk Agar (EYA; Difco). For selection of Clostri
dium species, aliquots of each dilution were treated at 80 1C
for 10 min to kill vegetative cells, leaving spore-formers for
enumeration as described by Summanen et al. (1993).
Enterobacteriaceae were enumerated with MacConkey Agar
(MAC; Difco).

Creation and normalization of TRFLP data
In the probiotic–prebiotic study, DNA was isolated accord
ing to Clement & Kitts (2000). 16S rRNA gene TRFLP
patterns were created and data were normalized following
the protocol in Kaplan et al. (2001) with TaqGolds (Applied
Biosystems, Foster City, CA) as the polymerase and DpnII
(New England Biolabs, Beverly, MA) as the digesting
enzyme.
In the probiotic–antibiotic study, samples were extracted
in triplicate using the MoBio Ultracleans soil DNA kit
(MoBio Laboratories, Carlsbad, CA) following manufac
turer’s protocol with the addition of ﬁve extra washes with
S4. The success of each extraction was determined by measur
ing the DNA concentration in the extraction product with a
Spectramaxs spectrophotometer (Molecular Devices, Palo
Alto, CA).
Polymerase chain reaction was performed using primers
homologous to conserved regions on the bacterial 16S rRNA
gene. The reverse primer 536-K2R (5 0 -GTA TTA CCG CGG
CTG CTG G-3 0 ) and the forward primer 46-Ba2F (5 0 -GCY
TAA CAC ATG CAA GTC GA-3 0 ), which was ﬂuorescently
labeled with a phosphamide dye (D4; GenSet, La Hoya, CA),
were used for each reaction. Reactions of 50 mL were carried
out using 1 mL of undiluted extraction product, 5 mL of 10 �
Buffer, 3 mL of 10 mM dNTP, 2 mL of 20 g mL�1 BSA, 7 mL of
25 mM MgCl2, 1 mL of each primer, and 0.3 mL of 5 U mL�1
TaqGolds (Applied Biosystems). Reaction temperatures
and times were 96 1C for 10 min; 35 cycles of 94 1C for
1 min, 46.5 1C for 1 min, 72 1C for 2 min; and 72 1C for
10 min. All reactions were performed in triplicate and then
combined using a MoBio Ultracleans PCR Cleanup Kit

(MoBio Laboratories) following the manufacturer’s proto
col. PCR products were quantiﬁed using a ﬂuorometer
tuned to the labeling dye.
An enzyme digest was performed on 75 ng of cleaned
PCR product using the restriction endonuclease HaeIII
(New England Biolabs). Each 40 mL digestion used 75 ng of
DNA, 1 U of enzyme, and 4 mL of buffer. The samples were
digested for 4 h at 37 1C and inactivated for 20 min at 65 1C.
The digestion products were ethanol precipitated and resus
pended in 20 mL of formamide and 0.25 mL of CEQ 600 base
pair standard. TRFLP proﬁles were obtained using a Beckman Coulter CEQ8000 DNA analysis system.
Terminal restriction fragment length in nucleotides, and
TRF peak area were exported from the CEQ8000 into EXCEL
(Microsoft, Seattle, WA). To standardize the data for com
parison between samples, the area under each TRF peak was
normalized to the total amount of DNA analyzed and
expressed as parts per million (ppm). Peaks with an area of
less than 5000 ppm (o 0.5% of the total for that sample)
were excluded from analysis to reduce noise.

Analysis of TRFLP data
For both studies, normalized TRFLP data sets were trans
formed by taking the square root of the area under each TRF
peak to de-emphasize large TRF peaks while still taking
relative abundance into account (Blackwood et al., 2003).
Transformed data were analyzed by principal components
analysis, cluster analysis with Euclidean distance
P
Þ2 Þ1=2 �, and Bray–Curtis
½ð 600
TRF¼60 ðAreaTRF;d1 � Area
�
P600TRF;d7��
�
similarity � ½100ð1 � ð TRF¼60 Area
� �1TRF;d1 � AreaTRF;d7 Þ
P600
�
�
�ð TRF¼60 AreaTRF;d1 þ AreaTRF;d7 Þ Þ�. All statistics were
performed using Minitab 14 (Minitab Inc., State College,
PA) and EXCEL.

Results and discussion
Some recent studies have relied on a simple visual compar
ison of raw molecular data to show treatment effects
(Tannock et al., 2000; Hayashi et al., 2002; Sakamoto et al.,
2003). Unfortunately, data analyzed in this way could be
quite misleading and may overlook subtle differences in
community structure. The large number of variables gener
ated by molecular proﬁle methods makes the use of multi
variate statistics essential. Generally, pairwise similarity or
distance measures are used and are implicit in both principle
components analysis and cluster analysis. Molecular proﬁle
data can be analyzed as presence–absence data (Simpson
et al., 2000; Donskey et al., 2003; Sakata et al., 2005) or
relative abundance data (Kaplan et al., 2001; Wang et al.,
2004; Jernberg et al., 2005), although when only presenceabsence data are analyzed, information that may be critical
to assess treatment effect is lost. Therefore, analyses of
treatment effects within individuals have generally involved

multivariate data reduction methods such as principle
components analysis or cluster analysis (Zoetendal et al.,
2002; Wang et al., 2004; Jernberg et al., 2005). Both these
methods were tested using data from two studies of treat
ment effects on human fecal microbiota.

Analysis of the probiotic--prebiotic study TRFLP
data
The goal of the probiotic–prebiotic study was to describe the
changes in human fecal microbial communities caused by
the ingestion of probiotic bacteria and/or prebiotic. The
initial analysis followed a standard approach for TRFLP
data, where principle components analysis score plots were
created for each treatment group (Fig. 1). The samples
clearly did not cluster by week, indicating a large amount
of subject-to-subject variability. Between-subject variation
in TRF patterns was clearly greater than within-subject
variability, as indicated by an obvious grouping by subject.
The problem of subject-to-subject variation is com
pounded with molecular proﬁle data compared to culture
data because many more variables are introduced. In some
cases, signiﬁcant results can be obtained when grouping
individual data. For example, Sakata et al. (2005) evaluated
the effect of infant breast-feeding grouping all subjects
together, but the high sample number in the study allowed
for some signiﬁcant results. Both Simpson et al. (2000) and
Wang et al. (2004) discussed subject-to-subject variation in
human intestinal microbiota. Other investigators (Zoeten
dal et al., 1998; Vanhoutte et al., 2004) emphasized that
individual humans have a unique intestinal microbiota.
Therefore, if possible, treatment effects must be evaluated
separately for each individual.
Since the principle components analysis score plots
grouped by treatment could not identify any treatment
effect, another common approach was attempted. Principle
components analysis score plots and Euclidean distance
cluster analysis dendrograms were created for each indivi
dual subject. For example, principle components analysis
plots for both subject 27 (treated with both probiotics and
prebiotics) and subject 10 (control) indicated that weeks 9
and 12 were more similar to each other than to the sample
from week 3 (Fig. 2). The dendrograms showed that weeks 9
and 12 were between 20% and 40% similar, whereas week 3
was 3–8% similar to weeks 9 and 12. Unfortunately, there is
really no way to evaluate the signiﬁcance of this apparent
difference in microbiota by sample week. In fact, these
differences may be entirely random.
It is tempting to categorize subjects’ responses to treat
ment based on these analyses. A treatment would have an
effect if the week 3 sample (pretreatment sample) were
different from the other two samples. Although sample-to
sample differences are visible in these individual analyses
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(Fig. 2), the problem is how to assess the statistical sig
niﬁcance of these differences (i.e. no way to obtain a Pvalue) and there is very little statistical power because there
are more than 200 variables (TRF peaks) and only three
samples for each subject. As a result, each sample has a 33%
chance of being the most different.
Both principle components analysis and the cluster
analysis method used for this study required the use of
Euclidean distance, which is not the best choice for calculat
ing distances with molecular proﬁle data (Rees et al., 2004).
Although Euclidean distance is the most commonly used in
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the literature; Rees et al. (2004) argue that Bray–Curtis
distances are superior due to the large blocks of zeros
present in molecular proﬁle data sets. Bray–Curtis similarity
was speciﬁcally designed for use with species abundance
data sets (Beals, 1984), it is less susceptible to bias intro
duced by large numbers of zero abundance data, and it takes
the relative abundance of each TRF peak into account when
comparing two patterns. TRFLP data often contains zero
values (a peak present in one pattern that is not seen in
another) and can cover as much as 2.5 orders of magnitude
variation in TRF peak area. Therefore, Bray–Curtis

Analysis of the antibiotic--probiotic study TRFLP
data

similarity is a preferable similarity measure when comparing
TRF patterns.
In the probiotic–prebiotic study, Bray–Curtis similarity
was calculated between weeks 3 and 9, weeks 3 and 12, and
weeks 9 and 12, and interval plots of those values were
created for each different treatment group (Fig. 3). With this
method, changes due to treatment should be very easy to
see; one might expect the similarity between week 3 and
week 9 samples to be the least of all three comparisons across
all treated subjects.
No within-baseline comparison was possible with this
sampling regime, but it was possible to estimate the repro
ducibility of the TRFLP method with fecal samples. Pairwise
comparisons were made of ﬁve replicate TRF patterns from
the same sample (replication from the DNA extraction
step), resulting in an average similarity of 83%. Intriguingly,
the variation from week to week in the probiotic treatment
group was the same as that seen in the reproducibility
experiment (Fig. 3). Therefore, there was no discernible
change due to treatment. The week-to-week variation for
the prebiotic groups was less than that seen in the reprodu
cibility experiment but all three pairwise similarities were
the same, as indicated by overlapping standard error bars.
Once again, this indicates there was no change due to treat
ment. The similarity of week 9 to week 12 control samples
was clearly higher than the other pairwise similarities, but
this cannot be explained by any particular treatment.
The negative results of this study were most clear after
using Bray–Curtis pairwise similarity. This made it possible
to visualize the lack of change in fecal bacterial communities
given the sampling regime in this study, where no statistical
measure with any power could be used. This study also
made it clear that a set of baseline samples must be included
in investigations of human fecal microbiota.
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when analyzing the data by individual instead of grouping by
treatment results in a drastic loss of statistical power, invali
dating multivariate hypothesis tests, such as MANOVA.
Principle components analysis and cluster analysis can
give a good visual representation of treatment effects in an
individual, clearly showing which samples cluster together
(Figs 2 and 5). Unfortunately, it is not possible to extract
statistical signiﬁcance from these clusters, which only allows
for a discussion of trends. However, the distance measures
that are used in principle components analysis and cluster
analysis can be used for statistical hypothesis testing. Dis
tance measures are, by deﬁnition, pairwise comparisons.
Thus, assessment of treatment effects requires comparison
of pretreatment samples (baseline) with posttreatment sam
ples. The natural variation in native microbiota can poten
tially mask treatment effects. Prior studies of stability in
intestinal microbiota assert that individuals are generally
stable (Zoetendal et al., 1998; Donskey et al., 2003; Van
houtte et al., 2004). However, as these studies did not
quantify stability, it is difﬁcult to identify a subject as having
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unstable intestinal microbiota. Clearly, a single baseline
sample does not allow for an assessment of natural varia
tion. Therefore, the collection of multiple baseline samples
per subject is advisable. A comparison of Fig. 3 (one baseline
sample per subject in the probiotic–prebiotic study) and Fig.
6 (three baseline samples per subject in the antibiotic–pro
biotic study) highlights the advantages of having multiple
baseline samples.
In the next analysis approach, Bray–Curtis similarity to
baseline (days 1–14) was calculated for each day after
antibiotic treatment. Similarity within baseline was also
calculated for each subject. By comparing within-baseline
similarity to similarity from day 21 to baseline it was clear
that the antibiotics had a signiﬁcant effect on fecal microbiota across all subjects (ANOVA, P o 0.001). The average
similarity of baseline samples compared to the first day after
antibiotics (day 21) was 42%, whereas the average similarity
within baseline (days 1–14) was 51%. Average similarity to
baseline at day 25 increased to 47% and was not significantly
different from within baseline at a 95% confidence level

Probiotic

when the anomalous results of day 48 were removed from
analysis, a trend revealing a difference could be detected at a
90% confidence level (P = 0.066).
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Fig. 6. Average Bray–Curtis similarity from baseline (days 1–14) for each
day after treatment using probiotic–antibiotic study terminal restriction
fragment length proﬁle data. Error bars represent one standard error.
Bray–Curtis similarity in percent is indicated on the left axis.

(P = 0.078). At day 34 the average similarity reached 49%
and at day 48 it had decreased to 46%. The significance of
the change at day 48 is not clear, especially since it occurred
in both the probiotic and placebo treatment groups and thus
cannot be solely attributed to the cessation of probiotic
ingestion at day 34.
To assess the effect of probiotic ingestion on changes
brought about by antibiotic treatment, the Bray–Curtis
similarity data were analyzed separately for probiotic and
placebo groups (Fig. 6). Both groups exhibited a similar
trend toward increased similarity to baseline over days 21
through 34, but the probiotic group exhibited a larger
increase in similarity at day 34. The difference between the
two groups was not signiﬁcant when all four postantibiotic
treatment days were analyzed (MANOVA, P = 0.135). However,
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The culture data were ﬁrst analyzed for antibiotic effects
using interval plots as a standard univariate method to look
for signiﬁcant differences with treatment (Fig. 7). However,
the large variation in counts (�1 log standard error) across
all subjects resulted in a loss of power for statistical analyses
and precluded detection of any signiﬁcant differences
(ANOVA). Increasing trends were visible in Bacteroides and
enterics at day 21. There was no trend seen for Clostridium,
Bifidobacterium, and Lactobacillus. Madden et al. (2005)
artificially reduced error by excluding uncountable plates
from their analyses. However, this approach is inappropriate
since it will bias the analysis, possibly leading to false
conclusions. Although analysis of culture data generally
involves univariate statistics, multivariate statistics can be
applied if multiple media are investigated. When Sullivan
et al. (2003) presented univariate analyses of culture data
they could only discuss trends, as no statistically significant
effects could be reported. However, multivariate statistics
may provide a more accurate way to test for treatment
effects. Unfortunately, MANOVA of data from all five culture
media also showed no statistical difference between bacterial
counts before antibiotic treatment compared to the days
after antibiotic treatment (MANOVA, P = 0.34). This may be
due to the subject-to-subject variation previously seen in the
TRFLP data.
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Fig. 7. Interval plots of log colony-forming units
of probiotic–antibiotic study culture data; all sub
jects, days 1–21. Error bars represent one standard
error. Panel a, BBE agar for organisms in the B.
fragilis group; panel b, BIM-25 agar for biﬁdobac
teria; panel c, egg yolk agar for Clostridium ssp.
spores; panel d, LBS agar for lactobacilli; panel e,
MacConkey agar for Enterobacteriaceae.

Euclidean distance was used to compare the average
distance of baseline samples (days 1–14) to the ﬁrst day after
antibiotics (day 21) for each subject. Euclidean distance was
used in this case because the standard assumptions of
normality and nonzero data are not violated with culture
data as they are with TRFLP data. When the effect of
antibiotics was evaluated on an individual subject basis in
the same way as with the TRFLP data, a signiﬁcant effect was
detected (ANOVA, P = 0.003). The average pairwise distance at
baseline was 3.3 compared to an average distance to baseline
of 4.2 after antibiotic treatment. At day 25 the distance to
baseline decreased to 3.5, not significantly different from
within baseline (P = 0.56). At day 34 the average distance to
baseline was 3.7 and at day 48 it was 3.5.
To assess the effect of probiotic ingestion on changes
brought about by antibiotic treatment, the Euclidean dis
tance data were analyzed separately for probiotic and
placebo groups (Fig. 8). Here the culture data showed a
much greater difference than the TRFLP data, with the
probiotic group maintaining an average distance to baseline
of around 3.6–3.7 throughout the study. In contrast, the
placebo group showed a large shift from baseline at day 21
and a return to near baseline thereafter. The difference
between the two groups was quite signiﬁcant when all four
postantibiotic treatment days were analyzed (MANOVA,
P = 0.004). When day 48 was removed from analysis there
was still a significant difference between groups (P = 0.046).
To account for individual variation and still determine
which media showed the largest change in fecal microbiota,
the average baseline counts for each subject were subtracted
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Summary and conclusions
There are a variety of ways to collect quantitative data for the
assessment of treatment effects on intestinal communities,
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Fig. 9. Difference from baseline (days 1–14)
interval plots of probiotic–antibiotic study cul
ture data for each day after treatment and each
medium. Error bars represent one standard
error. Panel a, BBE agar for organisms in the B.
fragilis group; panel b, BIM-25 agar for biﬁdo
bacteria; panel c, Egg Yolk Agar for Clostridium
ssp. spores; panel d, LBS agar for lactobacilli;
panel e, MacConkey agar for Enterobacteria
ceae.

48

from the counts for that subject on each day subsequent to
antibiotic treatment. Although these data could not be used
to statistically analyze an antibiotic effect, they still reﬂected
the signiﬁcant difference between the probiotic and placebo
treatment groups (MANOVA, P = 0.049) over the four postantibiotic treatment days (Fig. 9). Follow-up ANOVAs indi
cated that a probiotic effect was significant for bifidobacteria
(P = 0.030) and Enterobacteriaceae (P = 0.006), but not sig
nificant for the B. fragilis group (ANOVA, P = 0.104), Clostri
dium (P = 0.601) or lactobacilli (P = 0.772).

Probiotic

J

34

Fig. 8. Average Euclidean distance from baseline (days 1–14) of probio
tic–antibiotic study culture data for each day after treatment. Error bars
represent one standard error.
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including both culture and molecular methods. Culturing is
a common approach but can give an incomplete picture of
the intestinal microbiota as feces contain large numbers of
unculturable or difﬁcult to culture organisms. Media choice
and sample handling can also skew the data. Molecular
proﬁle methods such as DGGE and TRFLP may present a
broader view of the intestinal microbiota (Tannock et al.,
2000; Donskey et al., 2003; Wang et al., 2004).
Culture or molecular proﬁle data can be grouped by
treatment for univariate hypothesis testing as the compar
ison to baseline implicitly takes into account subject-to
subject variation in intestinal microbiota. A good way to
visually represent the pairwise distances is with interval
plots (Figs 3, 6, and 8). These interval plots clearly show the
signiﬁcant changes in community structure. For culture
data, the use of univariate analyses can be appropriate to
identify individual population effects, but only when they
are used after an appropriate multivariate analysis. Instead
of using the log CFU measurements (Fig. 7), however, the
proper univariate method uses the difference between a
subject’s own individual baseline and each posttreatment
measurement (Fig. 9).
The method of comparison to baseline within an indivi
dual before grouping by treatment provides both a good
visual representation of the data and a clearer indication of
treatment effects on intestinal microbiota than an evalua
tion of data grouped before analysis. This applies whether
the study has a positive result (probiotic–antibiotic study)
or a negative result (probiotic–prebiotic study). It is also
apparent from analyzing these two data sets that a large
within-subject sample size and multiple baseline samples are
necessary to accurately analyze treatment effects on intest
inal microbiota. In addition, it is important to use Bray–
Curtis distances for molecular proﬁle data. The use of
Euclidean distances is appropriate for culture data and
univariate analysis of culture data is signiﬁcant only if it
follows the appropriate multivariate method.
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